Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 3/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12373131 | 0.91 | SLC5A2 (0.35) | SLC5A2P2RY6MAP3K5HRH3 | |
| SCHEMBL12373105 | 0.85 | MAP3K5 (0.34) | SLC5A2P2RY6MAP3K5HRH3ITPR1 | |
| SCHEMBL12373130 | 0.85 | HTRA2 (0.31) | — | |
| SCHEMBL13338353 | 0.83 | MAP3K5 (0.34) | SLC5A2MAP3K5HRH3 | |
| SCHEMBL12373135 | 0.82 | — | — | |
| SCHEMBL13024540 | 0.79 | P2RY6 (0.43) | SLC5A2P2RY6HTR3AHRH3ITPR1 | |
| SCHEMBL10293847 | 0.77 | SLC5A2 (0.45) | SLC5A2P2RY6HTR3AHRH3ITPR1 | |
| SCHEMBL10293844 | 0.77 | SLC5A2 (0.41) | SLC5A2P2RY6HTR3AMAP3K5HRH3 | |
| SCHEMBL12373115 | 0.77 | — | — | |
| SCHEMBL12373128 | 0.76 | SLC5A2 (0.31) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | SLC5A2 1420/4885P2RY6 560/4885HTR3A 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.